Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 12.36 is strong.
Suzhou Novoprotein Scientific Co has a Altman Z-Score of 12.62, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Suzhou Novoprotein Scientific Co's Altman Z-Score or its related term are showing as below:
SHSE:688137'
s Altman Z-Score Range Over the Past 10 Years
Min: 10.44 Med: 15.41 Max: 25.46
Current: 12.36
During the past 8 years, Suzhou Novoprotein Scientific Co's highest Altman Z-Score was 25.46. The lowest was 10.44. And the median was 15.41.
Suzhou Novoprotein Scientific Co (SHSE:688137) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Novoprotein Scientific Co Altman Z-Score Chart
SHSE:688137 vs VRTX, REGN, RVMD: Altman Z-Score Comparison
For the Biotechnology subindustry, Suzhou Novoprotein Scientific Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Novoprotein Scientific Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Novoprotein Scientific Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Suzhou Novoprotein Scientific Co's Altman Z-Score falls into.
Suzhou Novoprotein Scientific Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Suzhou Novoprotein Scientific Co (SHSE:688137) has a Altman Z-Score of 12.62 as of Jul. 29, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Suzhou Novoprotein Scientific Co and its competitors. This is 18% below median its historical median of 15.41. Over the past decade, Suzhou Novoprotein Scientific Co's Altman Z-Score has ranged from 10.44 to 25.46. According to the industry distribution chart, Suzhou Novoprotein Scientific Co ranks #177 out of 928 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Suzhou Novoprotein Scientific Co's Altman Z-Score too high?
Suzhou Novoprotein Scientific Co's current Altman Z-Score of 12.62 is 18% below median its 10-year median of 15.41. Over the past 10 years, this metric has ranged from a low of 10.44 to a high of 25.46. The Biotechnology industry median Altman Z-Score is 2.44. Suzhou Novoprotein Scientific Co's value of 12.62 is 417.2% above this industry median. Based on the distribution chart, Suzhou Novoprotein Scientific Co ranks #177 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Novoprotein Scientific Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Novoprotein Scientific Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Novoprotein Scientific Co ranks #177 out of 928 companies for Altman Z-Score. This places Suzhou Novoprotein Scientific Co in the top 19% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.44. Suzhou Novoprotein Scientific Co's value of 12.62 is 417.2% above this benchmark. Historically, Suzhou Novoprotein Scientific Co's own Altman Z-Score has ranged from 10.44 to 25.46 over the past decade. While the company's 10-year median is 15.41 vs. the industry median of 2.44, Suzhou Novoprotein Scientific Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.44, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Novoprotein Scientific Co's current Altman Z-Score of 12.62 is 417.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Suzhou Novoprotein Scientific Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Novoprotein Scientific Co's current Altman Z-Score is 12.62, which is 18% below median its own 10-year median of 15.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Novoprotein Scientific Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Novoprotein Scientific Co (SHSE:688137) is currently considered Fairly Valued. The stock's GF Value™ is ¥37.73, compared to a current price of ¥34.76 — trading 7.9% below its estimated fair value. The current Altman Z-Score is 12.62, which is 18% below median its 10-year median of 15.41 and 417.2% above the Biotechnology industry median of 2.44. Suzhou Novoprotein Scientific Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Suzhou Novoprotein Scientific Co (SHSE:688137), the current Altman Z-Score is 12.62 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Novoprotein Scientific Co (SHSE:688137) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Novoprotein Scientific Co stock appears to be undervalued.
The current stock price of ¥34.76 is trading 7.9% below its estimated GF Value™ of ¥37.73.
GuruFocus considers Suzhou Novoprotein Scientific Co to be Fairly Valued.
Key valuation signals for SHSE:688137:
Altman Z-Score: 12.62 (18% below median its 10-year median of 15.41)
GF Value™: ¥37.73 vs. price of ¥34.76 (7.9% below fair value)
Industry Position: 417.2% above the Biotechnology median (#177 of 928)
No single metric tells the full story. See the SHSE:688137 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Novoprotein Scientific Co Business Description
Suzhou Novoprotein Scientific Co Ltd is a high-tech enterprise focusing on recombinant protein application solutions. Its main business is the research and development of target and cytokine proteins, recombinant antibodies, enzymes, and reagents, Production and sales, and providing related technical services.
62GF Score
Get the complete analysis for SHSE:688137
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688137 has been successfully added to your 
